Synthetic IgE peptide vaccine for immunotherapy of allergy

Chang Yi Wang, Alan M. Walfield, Xinde Fang, Bruce Hammerberg, John Ye, Ming Lie Li, Fan Shen, Ming Shen, Valerie Alexander, Donald Macglashan

Research output: Contribution to journalArticle

Abstract

An immunotherapeutic vaccine for allergy was produced by designing IgE-based synthetic peptide immunogens and selecting them for functional immunogenicity. The vaccine targets the binding site on IgE for the high affinity receptor FcεRI, by active immunization. The peptide target site on IgE heavy chain was selected from among the amino acid sequences for the Cε2, Cε3, and Cε4 domains. These were characterised by epitope mapping studies for cross-reactivity to IgE and functional antigenicity. A peptide, modified from positions 413-435 of a loop region of Cε3 and subjected to conformational constraint, elicited anti-IgE antibodies that blocked IgE-mediated histamine release. It was immunopotentiated by linkage to a promiscuous T helper site to produce a wholly synthetic chimaeric immunogen. This immunogen was shown to induce polyclonal site-specific anti-IgE antibodies that obstruct binding to FcεRI, inhibit histamine release by IgE-sensitised basophils, inhibit passive cutaneous anaphylaxis, and do not signal degranulation. Immunized dogs experienced significant reductions in total serum IgE.

Original languageEnglish (US)
Pages (from-to)1580-1590
Number of pages11
JournalVaccine
Volume21
Issue number15
DOIs
StatePublished - Apr 2 2003

Fingerprint

synthetic vaccines
Subunit Vaccines
subunit vaccines
synthetic peptides
immunotherapy
hypersensitivity
Immunotherapy
Immunoglobulin E
Hypersensitivity
histamine
antigens
peptides
vaccines
anaphylaxis
basophils
antibodies
Synthetic Vaccines
Histamine Release
cross reaction
linkage (genetics)

Keywords

  • IgE
  • Immunotherapy
  • Peptide

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Wang, C. Y., Walfield, A. M., Fang, X., Hammerberg, B., Ye, J., Li, M. L., ... Macglashan, D. (2003). Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine, 21(15), 1580-1590. https://doi.org/10.1016/S0264-410X(02)00732-6

Synthetic IgE peptide vaccine for immunotherapy of allergy. / Wang, Chang Yi; Walfield, Alan M.; Fang, Xinde; Hammerberg, Bruce; Ye, John; Li, Ming Lie; Shen, Fan; Shen, Ming; Alexander, Valerie; Macglashan, Donald.

In: Vaccine, Vol. 21, No. 15, 02.04.2003, p. 1580-1590.

Research output: Contribution to journalArticle

Wang, CY, Walfield, AM, Fang, X, Hammerberg, B, Ye, J, Li, ML, Shen, F, Shen, M, Alexander, V & Macglashan, D 2003, 'Synthetic IgE peptide vaccine for immunotherapy of allergy', Vaccine, vol. 21, no. 15, pp. 1580-1590. https://doi.org/10.1016/S0264-410X(02)00732-6
Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine. 2003 Apr 2;21(15):1580-1590. https://doi.org/10.1016/S0264-410X(02)00732-6
Wang, Chang Yi ; Walfield, Alan M. ; Fang, Xinde ; Hammerberg, Bruce ; Ye, John ; Li, Ming Lie ; Shen, Fan ; Shen, Ming ; Alexander, Valerie ; Macglashan, Donald. / Synthetic IgE peptide vaccine for immunotherapy of allergy. In: Vaccine. 2003 ; Vol. 21, No. 15. pp. 1580-1590.
@article{794789a21c334ba9b67c4e17877f9819,
title = "Synthetic IgE peptide vaccine for immunotherapy of allergy",
abstract = "An immunotherapeutic vaccine for allergy was produced by designing IgE-based synthetic peptide immunogens and selecting them for functional immunogenicity. The vaccine targets the binding site on IgE for the high affinity receptor FcεRI, by active immunization. The peptide target site on IgE heavy chain was selected from among the amino acid sequences for the Cε2, Cε3, and Cε4 domains. These were characterised by epitope mapping studies for cross-reactivity to IgE and functional antigenicity. A peptide, modified from positions 413-435 of a loop region of Cε3 and subjected to conformational constraint, elicited anti-IgE antibodies that blocked IgE-mediated histamine release. It was immunopotentiated by linkage to a promiscuous T helper site to produce a wholly synthetic chimaeric immunogen. This immunogen was shown to induce polyclonal site-specific anti-IgE antibodies that obstruct binding to FcεRI, inhibit histamine release by IgE-sensitised basophils, inhibit passive cutaneous anaphylaxis, and do not signal degranulation. Immunized dogs experienced significant reductions in total serum IgE.",
keywords = "IgE, Immunotherapy, Peptide",
author = "Wang, {Chang Yi} and Walfield, {Alan M.} and Xinde Fang and Bruce Hammerberg and John Ye and Li, {Ming Lie} and Fan Shen and Ming Shen and Valerie Alexander and Donald Macglashan",
year = "2003",
month = "4",
day = "2",
doi = "10.1016/S0264-410X(02)00732-6",
language = "English (US)",
volume = "21",
pages = "1580--1590",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

TY - JOUR

T1 - Synthetic IgE peptide vaccine for immunotherapy of allergy

AU - Wang, Chang Yi

AU - Walfield, Alan M.

AU - Fang, Xinde

AU - Hammerberg, Bruce

AU - Ye, John

AU - Li, Ming Lie

AU - Shen, Fan

AU - Shen, Ming

AU - Alexander, Valerie

AU - Macglashan, Donald

PY - 2003/4/2

Y1 - 2003/4/2

N2 - An immunotherapeutic vaccine for allergy was produced by designing IgE-based synthetic peptide immunogens and selecting them for functional immunogenicity. The vaccine targets the binding site on IgE for the high affinity receptor FcεRI, by active immunization. The peptide target site on IgE heavy chain was selected from among the amino acid sequences for the Cε2, Cε3, and Cε4 domains. These were characterised by epitope mapping studies for cross-reactivity to IgE and functional antigenicity. A peptide, modified from positions 413-435 of a loop region of Cε3 and subjected to conformational constraint, elicited anti-IgE antibodies that blocked IgE-mediated histamine release. It was immunopotentiated by linkage to a promiscuous T helper site to produce a wholly synthetic chimaeric immunogen. This immunogen was shown to induce polyclonal site-specific anti-IgE antibodies that obstruct binding to FcεRI, inhibit histamine release by IgE-sensitised basophils, inhibit passive cutaneous anaphylaxis, and do not signal degranulation. Immunized dogs experienced significant reductions in total serum IgE.

AB - An immunotherapeutic vaccine for allergy was produced by designing IgE-based synthetic peptide immunogens and selecting them for functional immunogenicity. The vaccine targets the binding site on IgE for the high affinity receptor FcεRI, by active immunization. The peptide target site on IgE heavy chain was selected from among the amino acid sequences for the Cε2, Cε3, and Cε4 domains. These were characterised by epitope mapping studies for cross-reactivity to IgE and functional antigenicity. A peptide, modified from positions 413-435 of a loop region of Cε3 and subjected to conformational constraint, elicited anti-IgE antibodies that blocked IgE-mediated histamine release. It was immunopotentiated by linkage to a promiscuous T helper site to produce a wholly synthetic chimaeric immunogen. This immunogen was shown to induce polyclonal site-specific anti-IgE antibodies that obstruct binding to FcεRI, inhibit histamine release by IgE-sensitised basophils, inhibit passive cutaneous anaphylaxis, and do not signal degranulation. Immunized dogs experienced significant reductions in total serum IgE.

KW - IgE

KW - Immunotherapy

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=0037413960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037413960&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00732-6

DO - 10.1016/S0264-410X(02)00732-6

M3 - Article

C2 - 12639479

AN - SCOPUS:0037413960

VL - 21

SP - 1580

EP - 1590

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -